NCT05503550|Unknown
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
2 other identifiers
CR10916964407564MMY4002
Study Type
expanded_access
Target
N/A
Locations
0 countries
Sites
N/A
Timeline
RegisteredAug 2022
Brief Summary
The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 12, 2022
Completed4 days until next milestone
First Posted
Study publicly available on registry
August 16, 2022
CompletedLast Updated
December 16, 2025
Status Verified
December 1, 2025
First QC Date
August 12, 2022
Last Update Submit
December 8, 2025
Conditions
Interventions
Sponsors & Collaborators
MeSH Terms
Conditions
RecurrenceMultiple Myeloma
Interventions
talquetamab
Condition Hierarchy (Ancestors)
Disease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsNeoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasmsHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersLymphoproliferative DisordersImmunoproliferative DisordersImmune System Diseases
Study Officials
- STUDY DIRECTOR
Janssen Research & Development, LLC Clinical Trial
Janssen Research & Development, LLC
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 12, 2022
First Posted
August 16, 2022
Last Updated
December 16, 2025
Record last verified: 2025-12